Immuneering Corp (IMRX) is not a good buy for a beginner, long-term investor at this time. The stock has shown significant recent price declines, weak financial performance, and lacks strong positive catalysts. While insider buying and analyst ratings are encouraging, the overall sentiment and technical indicators suggest caution.

Technical Analysis

The MACD is slightly positive but contracting, RSI is neutral at 46.303, and moving averages are converging, indicating no strong trend. The stock is trading near its support level (S1: 4.897), but the overall technical setup does not suggest a strong buying opportunity.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Insiders are buying with a 266.10% increase in the last month. Analyst Leerink has an Outperform rating, citing encouraging survival data from a Phase 2a trial.

Neutral/Negative Catalysts

The stock has dropped 40% recently, with no significant news or events to reverse the trend. Financial performance is weak, with negative EPS growth (-22.45% YoY) and no revenue growth. The next earnings report is over a month away, reducing the potential for near-term catalysts.

Financial Performance

In Q3 2025, the company reported no revenue growth (0% YoY), a net loss of -$14,964,875 (up 2.52% YoY), and a significant drop in EPS to -0.38 (-22.45% YoY). Gross margin remains at 0%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst Leerink has an Outperform rating, citing positive safety data and a potential niche in frailer patients. However, the stock has significantly declined recently, and there is no consensus upgrade or strong momentum in analyst sentiment.

4 Analyst Rating

Wall Street analysts forecast IMRX stock price to rise

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 4.990

Low

Averages

14.5

High

Current: 4.990

Low

Averages

14.5

High

Leerink

Outperform

maintain

$NULL

AI Analysis

2026-01-08

Reason

Leerink

Price Target

$NULL

AI Analysis

2026-01-08

maintain

Outperform

Reason

After Immuneering (IMRX) announced updated overall survival and safety data from its ongoing Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients, Leerink says the updated 12 month data highlights "impressive" 64% landmark OS, which the analyst calls "encouraging." The median progression free survival deteriorated to 8.5 months, which the analyst notes is similar to the 8.5 months shown by Revolution Medicines' (RVMD) daraxonrasib in second-line PDAC, but adds that Immuneering may have a safety advantage that "could facilitate a niche in frailer patients." Leerink has a Outperform rating on Immuneering shares, which are down $3.37, or 40%, to $4.96 in afternoon trading.

Leerink

Outperform

initiated

$15

2025-10-31

Reason

Leerink

Price Target

$15

2025-10-31

initiated

Outperform

Reason

Leerink initiated coverage of Immuneering with an Outperform rating and $15 price target. The firm notes lead asset atebimetinib is an allosteric MEK inhibitor that has shown compelling Phase 2 activity in combination with chemotherapy in first-line pancreatic ductal adenocarcinoma, a tumor type in which over 90% of patients are driven by aberrant, constitutive MAPK signaling. Leerink thinks DCI, which departs from conventional, continuous kinase inhibition and uses high dose, pulsatile blockade, introduces mechanistic risk. However, it sees significant upside if efficacy and tolerability are confirmed in the pivotal trial by allowing a more tolerable approach to MEK inhibition. The firm views atebi as a blockbuster+ agent in PDAC with $2.4B peak revenues, representing $14/share in its model.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IMRX

Unlock Now

IMRX Should I Buy

IMRX Should I Buy

Should You Buy Immuneering Corp (IMRX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch